Diroximel fumarate is a medicine for people with relapsing multiple sclerosis (MS). It is a capsule you swallow, usually twice a day. It works by calming the immune system so it does less damage to the nerves.
Every report comes from a Lived member, sent anonymously.
Have you tried Vumerity (Diroximel Fumarate) for MS (Multiple Sclerosis)?
Diroximel fumarate, sold as Vumerity, is a prescription capsule for adults with relapsing forms of multiple sclerosis (MS). That includes relapsing-remitting MS, where symptoms flare in attacks called relapses and then partly or fully settle; active secondary progressive MS, where disability gradually builds but relapses or new inflammation still occur; and clinically isolated syndrome, a first episode of MS-like symptoms. It is one of several disease-modifying therapies, long-term treatments meant to reduce new attacks and slow the damage MS causes, rather than to relieve day-to-day symptoms. Vumerity is closely related to dimethyl fumarate (Tecfidera and generics), an older MS pill. Both turn into the same active substance in the body, so they are expected to work about as well as each other. Vumerity was designed to be easier on the stomach, which is often the reason someone chooses it or switches to it.
In MS, the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. Each attack can cause a relapse and leave scars, called lesions, that show up on MRI (magnetic resonance imaging) scans of the brain and spinal cord. After it is swallowed, diroximel fumarate is quickly converted to monomethyl fumarate, the same active compound produced by dimethyl fumarate. Monomethyl fumarate switches on a cellular defense system (the Nrf2 pathway) that helps cells cope with oxidative stress, and it dampens inflammatory immune activity. Exactly how this translates into fewer MS relapses is not fully understood. Part of its effect on the immune system is a lowering of lymphocytes, a type of white blood cell, which is also why blood counts are monitored.
Vumerity comes as a 231 mg delayed-release capsule taken by mouth twice a day. People usually start with one capsule twice a day for the first week, then move to the full dose of two capsules twice a day. If side effects are hard to handle, the prescriber may lower the dose for a few weeks before returning to the full dose. Swallow the capsules whole. Do not crush, chew or open them and sprinkle the contents on food. Vumerity can be taken with or without food, but taking it with a heavy, high-fat meal (more than about 700 calories or 30 grams of fat) should be avoided, and so should drinking alcohol around the time of a dose. Blood tests are needed before the first dose: a complete blood count, including lymphocytes, and liver tests. Vumerity is not recommended for people with moderate or severe kidney impairment.
Flushing is the most common side effect: warmth, redness, itching or a burning feeling in the skin, usually starting soon after a dose. In trials of the closely related dimethyl fumarate it affected about 4 in 10 people, was mostly mild to moderate, and tended to ease over the first weeks. Taking the dose with food, or taking regular (non-coated) aspirin 30 minutes beforehand if the prescriber agrees, can reduce it. Flushing that is severe or does not ease is worth raising with the prescriber. Stomach pain, diarrhea and nausea are also common early on. In a 5-week head-to-head study, people taking Vumerity had fewer days of stomach symptoms than people on dimethyl fumarate, and far fewer stopped treatment because of them. Stop taking Vumerity and get emergency care for signs of a severe allergic reaction, such as trouble breathing, hives, or swelling of the face, throat or tongue. This can happen with the first dose or later. Stop the medicine and contact the care team right away about severe stomach pain, severe vomiting or diarrhea, rectal bleeding, bloody diarrhea or vomiting blood. Rarely, fumarate medicines have caused serious ulcers, bleeding or blockages in the gut, most often in the first six months. Also report promptly signs of an infection that is not clearing, a painful blistering rash that could be shingles, or possible liver injury: unusual tiredness, loss of appetite, discomfort in the upper right abdomen, dark urine, or yellowing of the skin or eyes. A rare, serious brain infection called progressive multifocal leukoencephalopathy (PML) has occurred with dimethyl fumarate, mostly in people whose lymphocyte counts stayed low for many months. Contact the care team promptly about new weakness on one side of the body, clumsiness, vision changes, or confusion and memory changes that worsen over days to weeks, even if they look like an MS relapse.
Vumerity must not be taken together with dimethyl fumarate (Tecfidera or a generic), because both produce the same active compound. Someone switching from dimethyl fumarate can start Vumerity the day after their last dose. People who have had an allergic reaction to either medicine should not take Vumerity. Because it can lower lymphocytes, Vumerity can make some infections more serious. If lymphocyte counts stay very low for more than six months, the prescriber may pause treatment. Make sure every doctor treating you knows you take it, especially before starting other medicines that affect the immune system. There is not enough information on Vumerity in pregnancy. Studies of pregnancies exposed to dimethyl fumarate, mostly in the first trimester, have not shown an increased rate of birth defects or miscarriage, but animal studies raised concerns, so pregnancy plans are worth discussing before starting. It is not known whether the drug passes into breast milk.
Flushing and stomach upset are usually most noticeable in the first month and often settle as the body adjusts. Vumerity does not make a person feel better from day to day in the way a symptom medicine might. Its benefit shows up over months and years as fewer relapses, fewer new lesions on MRI and a slower build-up of disability. In the main two-year trial of dimethyl fumarate, about 27% of people on the drug had a relapse, compared with 46% on placebo. Treatment is long term. The care team repeats a complete blood count about six months after starting and then every 6 to 12 months, checks liver tests as needed, and keeps tracking MS with regular neurological exams and MRI scans. If relapses or new lesions continue, or blood counts stay low, the team may suggest changing to another disease-modifying therapy. Stopping should be planned with the neurologist, because MS activity can return off treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Vumerity (Diroximel Fumarate), what you've noticed, or ask the community a question.